Zydus Healthcare gets CDSCO Panel Nod To study FDC Empagliflozin plus Metoprolol Succinate Dr. Divya Colin10 March 2024 5:45 PM ISTNew Delhi: The drug major Zydus Healthcare has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Synokem Pharma Gets CDSCO Panel Nod To Study Antidiabetic FDC Dr. Divya Colin27 Feb 2024 6:00 PM ISTNew Delhi: The drug major Synokem Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
CDSCO approves Jardiance for treatment of adults with chronic kidney disease in India Ruchika Sharma14 Feb 2024 5:49 PM ISTMumbai: The national regulatory authority of India, the Central Drugs Standard Control Organisation (CDSCO), has approved Jardiance...
Diabetes patients taking SGLT2 inhibitors may exhibit false positive urine ethanol tests: NEJM Medha Baranwal9 Feb 2024 11:15 AM ISTUSA: A recent article published in the New England Journal of Medicine described a patient with diabetes who was taking empagliflozin, an SGLT2...
Empagliflozin and semaglutide combination improves glycemic control and BP but not arterial stiffness Jacinthlyn Sylvia1 Feb 2024 10:15 AM ISTA recent 32-week study investigated the effects of empagliflozin, semaglutide, and their combination on vascular function. This study published in the...
Torrent Pharma Gets CDSCO Panel Nod To study antidiabetic FDC Empagliflozin plus Sitagliptin Dr. Divya Colin17 Jan 2024 6:00 PM ISTNew Delhi: The drug major Torrent Pharmaceutical has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
Novel aldosterone synthase inhibitor with concurrent empagliflozin reduces albuminuria in CKD patients: Lancet Medha Baranwal16 Jan 2024 7:00 AM ISTUSA: A randomised, controlled, phase 2 trial published in The Lancet has shed light on the safety and efficacy of aldosterone synthase inhibition with...
Empagliflozin may not exhibit clinical or mortality benefit in COVID-19 patients Jacinthlyn Sylvia5 Dec 2023 10:15 AM ISTThe RECOVERY trial has concluded that empagliflozin, a drug proposed for its anti-inflammatory and metabolic effects, does not provide substantial...
Conduct Phase III clinical trial: CDSCO to Zydus Healthcare over FDC Empagliflozin plus Sitagliptin Dr. Divya Colin12 Nov 2023 4:00 PM ISTNew Delhi: In response to the proposal presented by the drug major Zydus Healthcare, the Subject Expert Committee ( SEC) functional under the Central...
Aldosterone synthase inhibitor shows promise in CKD trial: Boehringer Ingelheim Ruchika Sharma5 Nov 2023 2:30 PM ISTGermany: Boehringer Ingelheim has announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor...
Dr Reddy's Gets CDSCO Panel Nod to Study Antidiabetic FDC Empagliflozin, Sitagliptin, Metformin tablet Dr. Divya Colin20 Oct 2023 6:00 PM ISTNew Delhi: The drug major Dr Reddy's Laboratories has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Empagliflozin lowers high BP and hyperuricemia in patients with type 2 diabetes Medha Baranwal18 Oct 2023 11:15 AM ISTChina: Treatment with the SGLT2 inhibitor Empagliflozin is effective in controlling hypertension and hyperuricemia in diabetes patients, a systematic...
